

Tildrakizumab (Ilumya®)

Selected References:

- English language version of Summary of Product Characteristics for Ilumetri (tildrakizumab) Accessed: <https://www.ema.europa.eu/en/medicines/human/EPAR/ilumetri#product-information-section>.
- Gisondi P, et al. 2022. Italian adaptation of EuroGuiDerm guideline on the systemic treatment of chronic plaque psoriasis. Ital J Dermatol Venerol. 157(Suppl. 1 to No. 1):1-78.
- Haycraft K, , et al. 2020. Outcomes of pregnancies from the tildrakizumab phase I-III clinical development programme. Br J Dermatol, 183: 184-186.
- Ilumya® Prescribing Information. Available online at https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761067s000lbl.pdf. Accessed on May 1, 2023.
- Owczarek W, et al. 2020. The use of biological drugs in psoriasis patients prior to pregnancy, during pregnancy and lactation: a review of current clinical guidelines. Postepy Dermatol Alergol. ;37(6):821-830.
- Smith C, , et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update. Br. J. Dermatol., 183: 628-637.
- Yeung J, , et al. 2020. Management of Plaque Psoriasis With Biologic Therapies in Women of Child-Bearing Potential Consensus Paper. J Cutan Med Surg. 24(1_suppl):3S-14S.

¿Preguntas? Llame al 866.626.6847 | Texto 855.999.3525 | Correo electrónico o chat en MotherToBaby.org .

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de febrero de 2023.

Tildrakizumab (Ilumya®)

Selected References:

- Cohen LS, et al. 2018. Risk of major malformations in infants following first trimester exposure to quetiapine.

Am J Psychiatry, 175:1225-1231.

- Damkier P, & Videbech P. 2018. The safety of second-generation antipsychotics during pregnancy: a clinically focused review. *CNS Drugs*, 32:351- 366.
- Ennis ZN., & Damkier P. 2015. Pregnancy exposure to olanzapine, quetiapine, risperidone, aripiprazole and risk of congenital malformations. A systematic review. *Basic Clin Pharmacol Toxicol*, 116:315-320.
- FDA Drug Safety Communication: Antipsychotic drug labels updated on use during pregnancy and risk of abnormal muscle movements and withdrawal symptoms in newborns: <https://www.fda.gov/drugs/drugsafety/ucm243903.htm>.
- Heinonen E, et al. 2022 Antipsychotic use during pregnancy and risk for gestational diabetes: a national register-based cohort study in Sweden. *CNS Drugs*, 36:529-539.
- Holt RI, & Peveler RC. 2011. Antipsychotics and hyperprolactinaemia: mechanisms, consequences and management. *Clin Endocrinol (Oxf)*; 74(2):141-147.
- Huybrechts KF, et al. 2016. Antipsychotic use in pregnancy and the risk for congenital malformations. *JAMA Psychiatry*, 73(9): 938-946.
- Kulkarni J, et al. 2014. A prospective cohort study of antipsychotic medications in pregnancy: the first 147 pregnancies and 100 one year old babies. *PLoS ONE*, 9(5):e947-988.
- Leutritz AL, et al. 2022. Psychotropic medication in pregnancy and lactation and early development of exposed children. *British Journal of Clinical Pharmacology*, 1-14.
- Levesque S, & Riley C. 2017. Fetal exposure to lamotrigine and quetiapine in two consecutive pregnancies. *Arch Womens Ment Health*; 20:237-339.
- Liu X, et al. 2022. Association of maternal antipsychotic prescription during pregnancy with standardized test scores of schoolchildren in Denmark. *JAMA Internal Medicine*; 182(10):1035-1043.
- Lusskin SI, et al. 2004. Prolactin elevation with ziprasidone. *Am J Psychiatry*; 161(10):1925.
- Peng M, et al. 2013. Effects of prenatal exposure to atypical antipsychotics on postnatal development and growth of infants: a case-controlled, prospective study. *Psychopharmacology*; 228:577-584.
- Shao P, et al. 2015. Effects of clozapine and other atypical antipsychotics on infants development who were exposed to as fetus: a post-hoc analysis. *PLoS One*; 10(4): 0123373.
- Sørensen MJ, et al. 2015. Risk of fetal death after treatment with antipsychotic medications during pregnancy. *PLoS One*; 10: 0132280.
- Staub L, et al. 2022. Association of antipsychotic drug exposure in pregnancy with risk of neurodevelopmental disorders a national birth cohort study. *JAMA Internal Medicine*, 182(5):522-533.
- Wichman CL. 2009. Atypical antipsychotic use in pregnancy: a retrospective review. *Arch Womens Ment Health*; 12:53-57.
- Yazdani-Brojeni P, et al. 2018. Quetiapine excretion into human breast milk. *J Clin Psychopharmacol*; 38:362-364.
- Zheng L, et al. 2022. Antidepressants and antipsychotics in human pregnancy: transfer across the placenta and opportunities for modeling studies. *Journal of Clinical Pharmacology*, 62(1):115-128.

¿Preguntas? Llame al 866.626.6847 | Texto 855.999.3525 | Correo electrónico o chat en MotherToBaby.org .

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de febrero de 2023.

Tildrakizumab (Ilumya®)

Selected References:

- American Academy of Pediatrics. 2021. Breastfeeding during the COVID-19 pandemic. Available at URL: <https://www.healthychildren.org/English/health-issues/conditions/COVID-19/Pages/Breastfeeding-During-COVID-19.aspx>
- Academy of Breastfeeding Medicine. 2020. ABM Statement: Considerations for COVID-19 vaccination in lactation. Available at URL: <https://abm.memberclicks.net/abm-statement-considerations-for-covid-19-vaccination-in-lactation>
- American College of Obstetricians and Gynecologists. 2021. COVID-19 vaccination considerations for obstetric-gynecologic care. Available at URL: <https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2020/12/covid-19-vaccination-considerations-for-obstetric-gynecologic-care>
- American Society for Reproductive Medicine. 2021. Patient management and clinical recommendations during the coronavirus (COVID-19) pandemic. Available at URL: <https://www.asrm.org/news-and-publications/covid-19/statements/patient-management-and-clinical-recommendations-during-the-coronavirus-covid-19-pandemic>
- Blakeway H, et al. 2022. COVID-19 vaccination during pregnancy: coverage and safety. *Am J Obstet Gynecol* 226(2): e1-236.e14.
- Centers for Disease Control and Prevention. 2022. Interim clinical considerations for use of COVID-19 vaccines currently approved or authorized in the United States: Considerations involving pregnancy, lactation, and fertility. Available at URL: <https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#pregnancy-fertility>
- Centers for Disease Control and Prevention. 2021. Vaccination safety for breastfeeding mothers. Available at URL: <https://www.cdc.gov/breastfeeding/breastfeeding-special-circumstances/vaccinations-medications-drugs/vaccinations.html>
- Citu IM, et al. 2022. Immunogenicity following administration of BNT162b2 and Ad26.COV2.S COVID-19 vaccines in the pregnant population during the third trimester. *Viruses* 14(2):307.
- Janssen Fact Sheet for Healthcare Providers Administering Vaccine. Revised 5/5/2022. Available at URL: <https://www.fda.gov/media/146304/download>
- Kachikis A, et al. 2021. Short-term reactions among pregnant and lactating individuals in the first wave of the COVID-19 vaccine rollout. *JAMA Netw Open* 4(8):e2121310.
- Kharbanda EO, et al. 2021. Spontaneous abortion following COVID-19 vaccination during pregnancy. *JAMA* 326(16):1629-1631.
- Lipkind HS, et al. 2022. Receipt of COVID-19 vaccine during pregnancy and preterm or small-for-gestational-age

at birth — Eight integrated health care organizations, United States, December 15, 2020–July 22, 2021. MMWR Morb Mortal Wkly Rep 2022;71:26–30.

- Morgan JA, et al. 2022. Maternal outcomes after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in vaccinated compared with unvaccinated pregnant patients. Obstet Gynecol 139:107–109.
- Moro PL, et al. 2022. Post-authorization surveillance of adverse events following COVID-19 vaccines in pregnant persons in the vaccine adverse event reporting system (VAERS), December 2020 – October 2021. Vaccine 40(24):3389–3394.
- Zambrano LD, et al. 2020. Update: characteristics of symptomatic women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status — United States, January 22–October 3, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:1641–1647.

¿Preguntas? Llame al 866.626.6847 | Texto 855.999.3525 | Correo electrónico o chat en [MotherToBaby.org](https://www.MotherToBaby.org) .

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de febrero de 2023.

Tildrakizumab (Ilumya®)

Selected References:

- Barenys M. 2009. Chronic exposure to MDMA (ecstasy) increases DNA damage in sperm and alters testes histopathology in male rats. Toxicol Lett 191:40–46
- Barneys M, et al. 2020. Developmental neurotoxicity of MDMA. A systematic literature review summarized in a putative adverse outcome pathway. Neurotoxicology 78:209–241.
- Committee on Drugs, American Academy of Pediatrics. 2001. The transfer of drugs and other chemicals into human milk. Pediatrics 108:776–89.
- Cooper AJ & Egleston CV. 1997. Accidental ingestion of Ecstasy by a toddler: Unusual cause for convulsion in a febrile child. J Accid Emerg Med 14(3):183–184.
- Draper ES, et al. 2008. Recreational drug use. A major risk factor for gastroschisis? Am J Epidemiol 167(4):485–491.
- Fríguls B, et al. A comprehensive review of assay methods to determine drugs in breast milk and the safety of

breastfeeding when taking drugs. Anal Bioanal Chem 397:1157-1179.

- Kolbrich EA, Goodwin RS, Gorelick DA, Hayes RJ, Stein EA, Huestis MA. 2008. Plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine after controlled oral administration to young adults. Ther Drug Monit. Jun;30(3):320-32.
- Marcela C, et al. 2019. Stimulant use in pregnancy – An under-recognized epidemic among pregnant women. Clin Obstet 62(1):168-184.
- McElhatton P, et al. 1999. Congenital anomalies after prenatal ecstasy exposure. Lancet 354:1441-2.
- Parrott A, et al. 2014. MDMA and heightened cortisol: a neurohormonal perspective on the pregnancy outcomes of mothers used 'Ecstasy' during pregnancy. Hum Psychopharmacol 29(1):1-7.
- Plessinger M, 1998. Prenatal exposure to amphetamines. Risks and adverse outcomes in pregnancy. Obstet Gynecol Clin North Am 25:119-38.
- Singer LT, et al. 2012. Neurobehavioral outcomes of infants exposed to MDMA (Ecstasy) and other recreational drugs during pregnancy. Neurotoxicol Teratol 34(3):303-10.
- Singer L. et al 2012. One-year outcomes of prenatal exposure to MDMA and other recreational drugs. Pediatrics 130(3): 407-413.
- Singer LT, et al. 2015. Developmental outcomes of 3,4-methylenedioxymethamphetamine (ecstasy)-exposed infants in the UK Hum Psychopharmacol 30(4): 290-294.
- Singer LT, et al. 2016. Motor delays in MDMA (ecstasy) exposed infants persist to 2 years. Neurotoxicol Teratol 54: 22-28.
- Smid MC, et al. 2019. Stimulant use in pregnancy: An under-recognized epidemic among pregnant women. Clin Obstet Gynecol 62(1):168-184.
- van Tonningen-van Driel MM, et al. 1999. [Pregnancy outcome after ecstasy use; 43 cases followed by the Teratology Information Service of the National Institute for Public Health and Environment (RIVM)]. Ned Tijdschr Geneesk 143(1):27-31.
- Woules TA, Lester BM. 2019. Stimulants: How big is the problem and what are the effects of prenatal exposure? Semin Fetal Neonatal Med 24(2):155-160.

¿Preguntas? Llame al 866.626.6847 | Texto 855.999.3525 | Correo electrónico o chat en [MotherToBaby.org](https://www.MotherToBaby.org) .

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de febrero de 2023.

Tildrakizumab (Ilumya®)

Selected References:

- Banihani SA, Khasawneh FH. 2018. Effect of lansoprazole on human sperm motility, sperm viability, seminal nitric oxide production, and seminal calcium chelation. *Res Pharm Sci.*13:460-468.
- Dağlı U, Kalkan IH. 2017. Treatment of reflux disease during pregnancy and lactation. *Turk J Gastroenterol.* 2017 Dec;28(Suppl 1):S53-S56.
- Diav-Citrin O, et al. 2005. The safety of proton pump inhibitors in pregnancy: A multicenter prospective controlled trial. *Aliment Pharmacol Ther.* 21:269-75.
- Escoffier, J, Arnaud, B, Kaba, M, et al. 2020. Pantoprazole, a proton-pump inhibitor, impairs human sperm motility and capacitation in vitro. *Andrology.* 8: 1795- 1804.
- Hastie R et al. 2019. Proton Pump Inhibitors and Preeclampsia Risk Among 157 720 Women. *Hypertension.* 73(5):1097-1103. doi: 10.1161/HYPERTENSIONAHA.118.12547.
- Kallen BA. 2001. Use of omeprazole during pregnancy-no hazard demonstrated in 955 infants exposed during pregnancy. *Eur J Obstet Gynecol Reprod Biol.* 96(1):63-68.
- Mahadevan U, Kane S. 2006. American Gastroenterological Association Institute technical review on the use of gastrointestinal medications in pregnancy. *Gastroenterology.*131(1):283-331
- Majithia R, Johnson DA. 2012. Are proton pump inhibitors safe during pregnancy and lactation? Evidence to date. *Drugs.* 72(2):171-179.
- Marshall JK, et al. 1998. Omeprazole for refractory gastroesophageal reflux disease during pregnancy and lactation. *Can J Gastroenterol.* 12(3):225-7.
- Matok I, et al. 2012. The safety of fetal exposure to proton-pump inhibitors during pregnancy. *Dig Dis Sci.* 57(3):699-705.
- Pasternak B, Hviid A. 2010. Use of proton pump inhibitors in early pregnancy and the risk of birth defects. *N Engl J Med.* 363(22): 2114-2123.
- Plante L, et al. 2004. Excretion of pantoprazole in human breast. *J Reprod Med.* 2004;49:825-7.
- Saito J, et al. 2020. Esomeprazole During Pregnancy and Lactation: Esomeprazole Levels in Maternal Serum, Cord Blood, Breast Milk, and the Infant's Serum. *Breastfeed Med.* 15(9):598-601. doi: 10.1089/bfm.2020.0175. Epub 2020 Jul 7.
- Ruigomez A, et al. 1999. Use of cimetidine, omeprazole, and ranitidine in pregnant women and pregnancy outcomes. *Am J Epidemiol.* 150(5):476-481.
- Thélin CS, Richter JE. 2020. Review article: the management of heartburn during pregnancy and lactation. *Aliment Pharmacol Ther.* 51(4):421-434. doi: 10.1111/apt.15611. Epub 2020 Jan 17. PMID: 31950535 Review.

¿Preguntas? Llame al 866.626.6847 | Texto 855.999.3525 | Correo electrónico o chat en [MotherToBaby.org](https://www.MotherToBaby.org) .

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de febrero de 2023.